DiRaimondo Thomas 4
4 · Janux Therapeutics, Inc. · Filed Jan 2, 2026
Insider Transaction Report
Form 4
DiRaimondo Thomas
Chief Scientific Officer
Transactions
- Sale
Common Stock
2026-01-02$13.73/sh−2,505$34,394→ 124,425 total - Award
Common Stock
2026-01-02+31,400→ 155,825 total - Award
Stock option (right to buy)
2026-01-02+109,900→ 109,900 totalExercise: $13.65Exp: 2036-01-01→ Common Stock (109,900 underlying)
Footnotes (4)
- [F1]The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units.
- [F2]Includes 4,049 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on May 15, 2025. Also, on January 3, 2025, the Reporting Person filed a Form 4 which inadvertently reported an aggregate of 7,781 shares acquired under the Plan. In fact, 5,432 of the shares were already reported as acquired by the Reporting Person under the Plan on a Form 3 filed on January 3, 2024 and 1,406 of the shares were reported as acquired by the Reporting Person under the Plan on a Form 4 filed on September 27, 2024.
- [F3]Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027.
- [F4]25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period.